Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04559009 · ClinicalTrials.gov registry record
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 47
- Enrollment target
NCT04559009 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 47 participants.
The verdict
NCT04559009 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2023-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04559009
The ClinicalTrials.gov registry entry for NCT04559009 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04559009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04559009 about?
NCT04559009 is a clinical study titled "COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry". Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sc...
What is the current status of trial NCT04559009?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2020-10-15. Estimated completion is 2023-01-31.
Who is sponsoring clinical trial NCT04559009?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.